The upregulated tumoral CD73 expression could thus impair the clinical efficacy of ICBs, supporting the rationale for targeting CD73 in combination with ICBs to enhance the anti-tumor immune response in the ICC ecosystem. Here, NT5E is linked to intrahepatic cholangiocarcinoma.